Letter Regarding Bad Ad Program

Dear Pharmaceutical Marketer:

As you know, the FDA has launched a new program to minimize misleading drug advertising and promotion. The “Bad Ad Program” has been designed such that healthcare professionals are being asked to proactively contact the FDA’s Division of Drug Marketing, Advertising, and Communications (DDMAC) if the HCP believes he/she has experienced any misleading or untruthful information conveyed in the promotion of a particular drug.

We would like to reassure you that IMC remains committed to maintaining the highest levels of promotional compliance to mitigate the risk for our clients. Ensuring that peer discussions remain on-label and all HCP communications are a truthful depiction of brand messages is our strength.

With our 25 year history without compliance violations, we continue to provide our clients with a high-impact method for communicating brand messages to physicians. IMC’s team of dedicated Moderators is rigorously trained in stimulating positive peer influence in a fully-compliant context. Additionally, our unique format for driving deep discussion is a fitting communications solution in an environment that is progressively more restrictive. Please rest assured that our priority is providing low-risk, high-impact services that help you reach your brand objectives.

If you have any questions, please contact us (info@informedmedical.com).